CSL's Financial Results
CSL's annual profit and final dividend announcement for 2018/19 was announced on 14th August 2019. Please click to view our historic Full Year and Half Year Financial Results.More Information
Search Results128 results found
CSL Limited ABN: 99 051 588 348 ASX Full-year information 30 June 2019 Lodged with the ASX under Listing Rule 4.3A.
NPAT at 30 June 2019 resulted in an above target performance, however CFO was below target (and above threshold).
CSL's exceptionally strong performance is a result of the focused execution of our strategy. Learn more.
CSL 2019 Full Year Announcement
Analyst Presentation Half Year Results 2019
We will announce our 2019 Full Year Results on Wednesday, 14th August 2019 (AEST)
We have announced our 2019 Half Year Results.
CSL Limited 2019 Full Year Results Paul Perreault, CEO and MD 14 August 2019 David Lamont, CFO LEGAL NOTICE
For immediate release 13 February 2019 Half Year Result 20191
CSL Limited is a global biotechnology manufacturer that researches, develops, and markets products to treat and prevent rare and serious diseases. Learn more.
CSL Limited Corporate Governance 2019 Driven by our promise, CSL is a global biotechnology leader which develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical